Compare TARS & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TARS | TMDX |
|---|---|---|
| Founded | 2016 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | 2020 | 2019 |
| Metric | TARS | TMDX |
|---|---|---|
| Price | $69.20 | $88.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | $89.00 | ★ $148.22 |
| AVG Volume (30 Days) | 831.4K | ★ 969.9K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 48.21 | ★ 382.18 |
| EPS | N/A | ★ 0.61 |
| Revenue | $451,360,000.00 | ★ $605,494,000.00 |
| Revenue This Year | $56.43 | $24.25 |
| Revenue Next Year | $30.19 | $18.75 |
| P/E Ratio | ★ N/A | $146.95 |
| Revenue Growth | ★ 146.71 | 37.13 |
| 52 Week Low | $48.20 | $60.11 |
| 52 Week High | $85.25 | $156.00 |
| Indicator | TARS | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 65.51 | 64.49 |
| Support Level | $60.95 | $66.64 |
| Resistance Level | $73.45 | $152.95 |
| Average True Range (ATR) | 3.30 | 4.31 |
| MACD | 1.12 | 1.16 |
| Stochastic Oscillator | 84.67 | 92.03 |
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.